ANK-101, an anchored IL-12 drug conjugate, induces immune responses and therapeutic activity in patients with HPV negative squamous cell carcinoma of the head and neck (HNSCC): A subset analysis of the Phase 1 ANCHOR clinical trial [WITHDRAWN]